PD-L1 IHC 28-8 pharmDx
Agilent Technologies, Inc. · Decision date Oct 9, 2015
What did the FDA approve?
FDA records P150025 as an original PMA application. The recorded decision is approval, dated Oct 9, 2015.
FDA approval order statement
APPROVAL FOR THE PD-L1 IHC 28-8 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING:1) PD-L1 IHC 28-8 PHARMDX IS A QUALITATIVE IMMUNOHISTO-CHEMICAL ASSAY USING MONOCLONAL RABBIT ANTI-PD-L1, CLONE 28-8 INTENDED FOR USE IN THE DETECTION OF PD-L1 PROTEIN IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48; 2) PD-L1 PROTEIN EXPRESSION IS DEFINED AS THE PERCENTAGE OF TUMOR CELLS EXHIBITING POSITIVE MEMBRANE STAINING AT ANY INTENSITY; AND3) PD-L1 EXPRESSION AS DETECTED BY PD-L1 IHC 28-8 PHARMDX IN NON-SQUAMOUS NSCLC MAY BE ASSOCIATED WITH ENHANCED SURVIVAL FROM OPDIVO (NIVOLUMAB).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Oct 9, 2015
Regulatory record facts
- Identifier
- P150025
- Regulatory pathway
- Premarket approval application
- Applicant
- Agilent Technologies, Inc.
- Product code
- Not reported
- Decision code
- APPR
- Decision date
- Oct 9, 2015
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
- Applicant
- Agilent Technologies, Inc.
- Product code
- Not reported
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P150025 received
Application receipt date recorded by FDA.
P150025 · FDA decision
APPR
P150025/S020 · Related supplement
PD-L1 IHC 28-8 pharmDx
P150025/S019 · Related supplement
PD-L1 IHC 28-8 pharmDx
Timeline entries are records held by MedtechLedger for P150025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PD-L1 IHC 28-8 pharmDxP150025/S020 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
PD-L1 IHC 28-8 pharmDxP150025/S019 | Agilent Technologies, Inc. | PMA supplement | Sep 21, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5301 Stevens Creek Blvd., Santa Clara, CA, 95051
Sources and methodology
- Original FDA record: P150025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
